Evidence map›Paper›PMID 40283908›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

AHR Agonist ITE Boosted PD1 Antibody's Effects by Inhibiting Myeloid-Derived Cells Suppressive Cells in an Orthotopic Mouse Glioma Model.

Pei Gong, Lijiao Zhao, Yunlong Ma, Qiuting Shu, Hui Sun, Jing Lu, Fanhua Meng, Fang Wan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pei GongTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Lijiao ZhaoTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Yunlong MaTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Qiuting ShuTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Hui SunTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Jing LuTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.
Fanhua MengTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.ORCID 0009-0005-3229-8651
Fang WanTumor Molecular Pharmacology Laboratory, College of Life Sciences, Inner Mongolia Agricultural University, Hohhot 010011, China.ORCID 0000-0001-5097-9227

Funding

Department of Science and Technology of Inner Mongolia Autonomous Region 2020MS08105Department of Science and Technology of Inner Mongolia Autonomous Region 2023MS08007Inner Mongolia Autonomous Region Education Department Natural Science Fund NJZY21472Inner Mongolia Autonomous Region Education Department University Innovation Team Fund NMGIRT2219Inner Mongolia endemic livestock biotechnology innovation team BR22-13-15National Natural Science Foundation of China 81460455
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AHRglioblastomaIL11ITEPD1

Identifiers

PMID40283908
PMCPMC12030425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.